AMH and polycystic ovary syndrome: Whilst there is moderate evidence from multiple RCTs and meta-analyses that individualised gonadotropin dosing based on ovarian reserve testing (by AMH level) results in a reduced risk of moderate and severe OHSS, all of these studies specifically excluded patients with PCOS (59–62).